Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients With Genotype 1 Hepatitis C Virus Using Super-Early Viral Response Within 2 Weeks
Journal of Liver
doi 10.4172/2167-0889.1000217
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
OMICS Publishing Group